Mode
Text Size
Log in / Sign up

Dimethyl fumarate with slow titration improves treatment satisfaction and quality of life in Iranian MS patientsOral Pill Beats Shots for MS Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider patient-reported benefits of DMF with slow titration, but note study limitations and lack of safety data.

This evidence comes from a multicenter, phase 4, open-label, single-arm observational study conducted in Iran. The study population comprised 645 patients with relapsing-remitting multiple sclerosis (RRMS) who were initiating treatment with dimethyl fumarate (DMF). Participants were either treatment-naïve or switching from prior injectable disease-modifying therapies. The study followed these patients for 12 months in a real-world clinical setting, with no randomized comparator group; all outcomes were compared to patient baseline status prior to DMF initiation.

The intervention was oral dimethyl fumarate administered with a specified slow-dose titration regimen. The exact dosing protocol (e.g., starting dose, titration schedule, and maintenance dose) was not reported in the provided data. As a single-arm study, the formal comparator was each patient's own baseline assessment across all measured parameters. The study's primary focus was on patient-reported outcomes rather than traditional clinical efficacy measures like relapse rate or MRI activity.

The primary outcome was the change in treatment satisfaction from baseline to month 12 among previously treated patients, measured by the Treatment Satisfaction Questionnaire for Medication (TSQM-14). Results showed statistically significant improvements across all TSQM-14 domains: effectiveness (increase of +13.01 points, p < 0.001), side effects (increase of +7.76 points, p < 0.001), convenience (increase of +35.21 points, p < 0.001), and global satisfaction (increase of +15.75 points, p < 0.001). The magnitude of improvement was largest for the convenience domain. Absolute numbers for these scores were not reported.

Key secondary outcomes also showed statistically significant favorable changes. Health-related quality of life measured by the EQ-5D-3L showed a utility score improvement of +0.07 (p < 0.001) and a Visual Analogue Scale (VAS) improvement of +3.86 points (p < 0.001). Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) improved, with a score reduction of -1.62 points (p < 0.001), indicating better sleep. Work productivity measured by the Work Productivity and Activity Impairment (WPAI) questionnaire showed a -7.55% change in absenteeism (p < 0.001). Depressive symptoms improved significantly (BDI-7 change −0.11, p<0.001).

Adverse events declined over time, confirming a favorable and manageable safety profile. Gastrointestinal adverse events led to discontinuation in 45 patients (26.0%). The reported improvement in the TSQM-14 'side effects' domain suggests a perceived benefit, but without absolute safety data, a full tolerability profile cannot be assessed from this evidence alone.

These results add a patient-centered perspective to the existing body of evidence for DMF in RRMS. Prior landmark randomized controlled trials (DEFINE and CONFIRM) established DMF's efficacy in reducing relapse rates and MRI lesions. This observational study suggests that in a real-world Iranian population, initiating DMF—particularly with a slow titration—is associated with meaningful improvements in how patients perceive and experience their treatment, which complements the known efficacy data. The large improvement in convenience likely reflects the transition from injectable therapies to an oral medication.

Key methodological limitations must be considered. As an open-label, single-arm, observational study without a control group, the observed improvements cannot be definitively attributed to DMF alone; they may be influenced by placebo effects, regression to the mean, or the natural course of the disease. The study was conducted solely in Iran, which may limit generalizability to other geographic and healthcare settings. The absence of reported clinical efficacy endpoints (relapses, disability progression, MRI) means the correlation between improved patient-reported outcomes and disease control is unknown. Furthermore, the lack of detailed safety reporting is a significant gap.

The clinical implications are that for patients with RRMS in similar settings, a slow titration of DMF may be associated with improved treatment satisfaction and quality of life over 12 months, especially for those switching from injectables. Clinicians might consider these patient-reported benefits when discussing treatment options, while continuing to monitor for known safety signals like lymphopenia and GI intolerance. However, treatment decisions should still be primarily guided by efficacy and safety data from controlled trials.

Several important questions remain unanswered. How do these patient-reported outcomes correlate with clinical and radiological disease activity? What were the specific adverse event rates and reasons for discontinuation? How does the slow titration regimen used compare to standard titration in terms of tolerability and efficacy? Would these results be replicable in a controlled trial with a comparator arm? Long-term data beyond 12 months are also needed to see if these improvements are sustained.

Imagine waking up and taking a simple pill instead of a painful injection. Now imagine that pill also helps you sleep better and feel less depressed.

That is the promise of a new study on dimethyl fumarate (DMF).

Multiple sclerosis (MS) is a disease that attacks the nerves in the brain and spinal cord. It can cause weakness, numbness, and vision problems.

Many people with relapsing-remitting MS (RRMS) have to take monthly shots. These injections can be painful and hard to remember.

Patients often feel frustrated by this routine. They worry about missing a dose or dealing with side effects.

Doctors want treatments that fit better into daily life. They want options that improve how patients feel, not just how their disease looks on a scan.

The Surprising Shift

For years, doctors focused mostly on stopping disease activity. They used scales to measure if the disease was slowing down.

But these scales miss how a patient actually feels. They do not measure sleep, mood, or job performance.

This study changes the focus. It looks at what matters most to the patient: satisfaction and quality of life.

But here is the twist. The study found that an oral pill could improve these areas just as well as, or better than, the old shots.

Think of your body like a busy highway. In MS, traffic jams block the flow of signals.

DMF acts like a traffic cop. It helps clear the blockages and keeps the signals moving.

The pill is special because it is taken by mouth. This makes it much easier to take than a shot.

The study used a slow-start method. Doctors began with a low dose and slowly increased it. This helps avoid stomach upset.

Researchers in Iran watched 645 patients over one year.

Half of these patients had never taken MS medicine before. The other half had switched from shots to this pill.

They took the pill every day for 12 months. Doctors checked in with them every month to track progress and safety.

The results were very positive for patients who had taken MS medicine before.

Their satisfaction with the treatment went up by 16 points. They felt the pill worked better and had fewer side effects.

They also felt more convenient taking a pill than a shot.

Sleep quality improved significantly. Patients reported feeling less tired and more rested.

Work productivity also went up. People missed fewer days at work because of MS symptoms.

Even mood improved. Scores for depression dropped slightly, showing the pill helped mental health too.

This doesn't mean this treatment is available yet.

That is not the full story. About 27% of patients stopped taking the pill during the year.

Most of these patients stopped because of stomach issues like nausea or diarrhea.

However, these side effects often went away after the body adjusted to the medicine.

If you have MS and hate injections, this is good news.

It shows that an oral option exists for many people. It can improve your daily life in many ways.

You should talk to your doctor about your options. Ask if a pill might work for you.

Do not stop your current medicine without asking your doctor first.

This study was done in one country. It only looked at one specific type of MS medicine.

Also, about a quarter of patients stopped taking the pill. This is a real-world issue doctors must solve.

Stomach problems are the main reason people quit. Doctors are working on ways to reduce these issues.

More studies are needed to confirm these results in other countries.

Doctors will likely compare this pill directly with other common MS shots.

If the pill proves safe and effective, it could become a standard choice for many patients.

Research takes time. We need to see long-term data before making big changes.

But the message is clear. Oral medicine is a powerful tool for managing MS.

Study Details

Study typePhase4
Sample sizen = 645
EvidenceLevel 2
Follow-up12.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Oral therapies for relapsing-remitting multiple sclerosis (RRMS) may enhance treatment satisfaction and quality of life. Patient-reported outcome measures (PROMs) provide structured insight into treatment effectiveness and disease impact beyond clinician-reported scales. OBJECTIVE: To assess treatment satisfaction and other PROMs in RRMS patients initiating dimethyl fumarate (DMF), either treatment-naïve or switching from injectable therapies. METHODS: PROFIT was a 12-month, multicenter, phase 4, open-label, single-arm observational study conducted in Iran. Patients received DMF with a slow-dose titration regimen to mitigate gastrointestinal adverse effects. The primary endpoint was the change in treatment satisfaction, assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM-14), from baseline to month 12 among previously treated patients. Key secondary endpoints included changes in additional PROMs, including health-related quality of life (HRQoL), depressive symptoms, sleep quality, and work productivity. Patient-reported outcomes were assessed using the EuroQol-5D-3L (EQ-5D-3L), Beck Depression Inventory-Fast Screen (BDI-7), Pittsburgh Sleep Quality Index (PSQI), and Work Productivity and Activity Impairment-Multiple Sclerosis (WPAI-MS) at baseline, 6 months, and 12 months. Adverse events were monitored monthly, with safety evaluated as a secondary outcome. RESULTS: Of 645 patients (72.3 % female; mean age 34.0 years), 473 (73.3 %) completed the 12-month follow-up, while 172 (26.7 %) discontinued treatment. The primary endpoint, change in treatment satisfaction (TSQM-14) among previously treated patients, showed significant improvement across all domains: effectiveness (+13.01), side effects (+7.76), convenience (+35.21), and global satisfaction (+15.75) (all p < 0.001). Secondary endpoints also demonstrated favorable changes, including EQ-5D-3L utility (+0.07), EQ-5D Visual Analogue Scale (VAS) (+3.86), PSQI (-1.62), WPAI absenteeism (-7.55 %), and BDI-7 (-0.11) (all p < 0.001). Treatment discontinuations (26.7 %) were primarily due to gastrointestinal adverse events (n = 45, 26.0 %), followed by physician decision (n = 34, 20.0 %), disease progression (n = 26, 15.0 %), patient preference (n = 19, 11.0 %), pregnancy (n = 14, 8.0 %), elevated liver enzymes (n = 13, 7.0 %), and other causes (n = 21, 12.0 %). Adverse events declined over time, confirming a favorable and manageable safety profile. CONCLUSION: DMF was associated with improvements in treatment satisfaction, quality of life, sleep quality, work productivity, and depressive symptoms in both treatment-naïve and previously treated RRMS patients, with high adherence and manageable side effects. These findings provide real-world evidence from an Iranian RRMS cohort, supporting DMF as a well-tolerated, patient-centered option with multidimensional benefits observed under routine clinical conditions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.